Denosumab biosimilar(Curateq Biologics)

地舒单抗生物类似药（Curateq Biologics）

Report date: 2024/02/29 17:26:36

Base Information

Drug NameDenosumab biosimilar(Curateq Biologics)

Drug Alias NameBP-16

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors

TargetsTumor necrosis factor ligand superfamily member 11

Therapy Area/IndicationsOsteoporosis, Postmenopausal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryWorldAustralia and New Zealand

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsOsteoporosis, Postmenopausal

Inactive IndicationsN/A

ATC CodeM05BX04